From one to many

Actio Biosciences was founded on an understanding that developing new drugs for rare diseases can inform novel treatment approaches for common diseases.
Actio has built an integrated drug discovery engine that leverages deep expertise in human genetics and bioinformatics to identify shared biology between rare and common diseases. Through the development of precision medicines for homogenous rare patient populations, Actio builds on a foundation of data to rationally target large, heterogeneous patient populations.

Actio is developing a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver better medicines for all patients. Founded in October 2021 and built on the experience of Drs. David Goldstein and John McHutchison, Actio is funded by EcoR1, Droia, and Deerfield Management.


Focus on unmet
patient needs


and respect

Join Us

We believe that advancing new treatments for diseases that affect one patient is fundamentally as important as advancing new treatments for diseases that affect many. Come join an exciting and rapidly growing team that is grounded in the science of precision medicine and dedicated to discovering transformational therapies for patients with severe unmet medical needs.

Our Current Job Listings

We are always looking for talented individuals who can contribute to our mission. If you’re passionate about developing transformational platforms and medicines and up for the challenge, contact us or send your resume to We will reach out if we have an opening that fits your qualifications.If you don’t see a job that suits you but think you’d be indispensable, reach out and tell us why.

Equal Employment Opportunities

All qualified applicants will receive consideration for employment without regard to race, religion, sex, sexual orientation, gender identity, or national origin.